Hughes Hubbard & Reed acted as legal adviser to Clinquest Group B.V. in the sale of its US and Dutch subsidiaries to Accelovance Inc., a Rockville, Maryland-based global Contract Research Organization (CRO) focusing on oncology vaccines and general medicine clinical research.
Under the terms of the deal, announced Dec. 2, 2015, Accelovance acquired Clinquest Inc. and Clinquest Services BV. The sale will help Accelovance expand its existing US and European footprint, while providing the company with extensive expertise in pharmacovigilance services.
"We're excited to be joining Accelovance and to be contributing to their growth and expansion," said Dr. Cornelis Wortel, founder and chief medical officer of Clinquest. "This is a great match and benefits both our employees and customers and allows us to offer our areas of expertise, especially in data management/biostatistics and pharmacovigilance services, to an expanded set of drug development clinics."
Clinquest has been providing CRO services to the pharmaceutical industry for more than 15 years, focusing on comprehensive clinical development and pre- and post-marketing pharmacovigilance services.
The Hughes Hubbard team included Jim Delaney, Jerry Harrison and Christine Lamsvelt.